AGTC Announces Participation in Upcoming Conferences

GAINESVILLE, Fla., April 27, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced its participation in the following upcoming conferences.

Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) – Denver, Colo. (May 3-7, 2015)

  • Researchers from Michigan State University, AGTC and the University of Pennsylvania will present new preclinical data evaluating the efficacy of an investigational adeno-associated virus (AAV) vector gene therapy developed by AGTC for the treatment of achromatopsia, a rare inherited retinal disease. The study (abstract #2066), titled "Long-term Cone ERG Functional Rescue in CNGB3 Mutant Achromatopsia Dogs by AAV-hCNGB3 Vectors Containing the PR1.7 Promoter and Packaged in AAV5, AAV9 or Mutant AAV2 Capsids," will be presented in an oral session from 5:00-5:15pm MT on May 4th.
  • AGTC will present new preclinical data evaluating the efficacy of recombinant AAV expressing hCNGB3 driven by various promoters in CNGB3 knock-out mice. The study (abstract #5477), titled "Rescue of Cone ERG Function by Treatment with AAV-hCNGB3 Vectors in CNGB3 Knockout Mice," will be presented in a poster session from 8:30-10:15am MT on May 7th.

BioFlorida Celebration of Biotechnology – Alachua, Fla. (May 7, 2015)

  • AGTC will be a sponsor of the BioFlorida Celebration of Biotechnology, an annual event for the Florida life sciences community hosted by BioFlorida.

American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting – New Orleans, La. (May 13-16, 2015)

  • AGTC will present new preclinical data related to the safety of the company's AAV vector gene therapies for the treatment of achromatopsia and X-linked retinoschisis. Additional new safety data will be presented on the company's proprietary manufacturing process. The new results will be presented in four abstracts:
    • Abstract #350775 – Safety and Biodistribution Study of rAAV2tYF-CB-hRS1 in RS1-deficient Mice
    • Abstract #350780 – Safety and Biodistribution Study of rAAV2tYF-CB-hRS1 in Nonhuman Primates
    • Abstract #350277 – Initial Safety Evaluation of rAAV-hCNGB3 Vectors in Nonhuman Primates
    • Abstract #350887 – Efficient Clearance of Herpes Simplex Virus Using a GMP-compliant Method for Production of Recombinant Adeno-associated Virus Vectors

Piper Jaffray GenomeRx Symposium – New York, N.Y. (May 20-21, 2015)

  • On May 20th at 1:45pm ET, Sue Washer, President and CEO, will participate in the Gene Therapy Vector Evolution Panel taking place as part of the Piper Jaffray GenomeRx Symposium.

Boston CEO Conference – Boston, Mass. (May 26-27, 2015)

  • On May 27th at 4:00pm ET, Stephen Potter, Chief Business Officer, will participate in a panel discussion entitled "Genetic Therapies: The Promise and The Challenge." The Boston CEO Conference is a networking forum for industry CEOs and decision makers in the life sciences.

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also pursuing pre-clinical development of treatments for wet AMD using the company's experience in ophthalmology to expand into disease indications with larger markets.

Forward Looking Statements

This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs. Forward-looking statements include information concerning possible or assumed future results of operations, business strategies and operations, preclinical and clinical product development and regulatory progress, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors, including, without limitation, those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2014, as filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACT: David Carey Lazar Partners Ltd. T: (212) 867-1768 Corporate Contact: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204

Source:Applied Genetic Technologies